Tranexamic acid (TXA) reduces surgical blood loss and alleviates inflammatory response in total hip arthroplasty. However, studies have not identified an optimal regimen. The objective of this study was to identify the most effective regimen of multiple-dose oral TXA in achieving maximum reduction of blood loss and inflammatory response based on pharmacokinetic recommendations. We prospectively studied four multiple-dose regimens (60 patients each) with control group (group A: matching placebo). The four multiple-dose regimens included: 2-g oral TXA 2 hours pre-operatively followed by 1-g oral TXA 3 hours post-operatively (group B), 2-g oral TXA followed by 1-g oral TXA 3 and 7 hours post-operatively (group C), 2-g oral TXA followed by 1-g oral TXA 3, 7 and 11 hours post-operatively (group D) and 2-g oral TXA followed by 1-g oral TXA 3, 7, 11 and 15 hours post-operatively (group E). The primary endpoint was estimated blood loss on post-operative day (POD) 3. Secondary endpoints were thromboelastographic parameters, inflammatory components, function recovery and adverse events. Groups D and E had significantly less blood loss on POD 3, with no significant difference between the two groups. Group E had the most prolonged haemostatic effect, and all thromboelastographic parameters remained within normal ranges. Group E had the lowest levels of inflammatory cytokines and the greatest range of motion. No thromboembolic complications were observed. The post-operative four-dose regimen brings about maximum efficacy in reducing blood loss, alleviating inflammatory response and improving analgaesia and immediate recovery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0038-1676625 | DOI Listing |
J Oral Maxillofac Surg
November 2024
Director, Jaw Deformities Care Program, Attending Surgeon, Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA; Director, Jaw Deformities Care Program, Attending Surgeon, Division of Plastic and Reconstructive Surgery, Keck School of Medicine of USC, Los Angeles, CA. Electronic address:
Eur Arch Otorhinolaryngol
November 2024
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Facial Plast Surg Aesthet Med
November 2024
Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Melasma is a chronic skin pigmentation disorder, and intradermal injection of tranexamic acid (TXA) is an effective treatment option for melasma with limited comparative efficacy studies. To compare the effectiveness of TXA injections with other treatment modalities for patients with melasma, as measured by Melasma Area and Severity Index (MASI). A total of 17 eligible randomized controlled trials were included in the meta-analysis.
View Article and Find Full Text PDFPlast Reconstr Surg Glob Open
November 2024
Dallas Plastic Surgery Institute, Dallas, Tex.
Background: Perioperative bleeding is a challenge in rhinoplasty and septoplasty. Tranexamic acid (TXA) may help reduce this, but its effectiveness is unclear. This systematic review and meta-analysis aimed to evaluate TXA's impact on bleeding in these procedures.
View Article and Find Full Text PDFClin Neurol Neurosurg
November 2024
Department of Orthopedics, Lianyungang Clinical College of Nanjing Medical University, 6 Zhenhua East Rd, Lianyungang 221000, China. Electronic address:
Background: Tranexamic acid (TXA) can effectively reduce intraoperative blood loss and transfusion rates. However, in spinal surgery, the number of surgical levels can significantly influence intraoperative and postoperative bleeding, particularly among the elderly, contributing to the persistently high rate of transfusion during the perioperative period. To verify the safety and efficacy of different application methods of TXA in elderly patients undergoing transforaminal lumbar interbody fusion (TLIF), a prospective cohort study was conducted.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!